STATE OF THE ART AT AAIC 2017 This year’s Alzheimer’s Association International Conference (AAIC) is the largest yet with 5,600 experts from around the world representing medical institutions, academia and industry. It is striking that the field now appears to…
Results from recent Alzheimer’s disease trials validate the ProMIS approach Johanne Kaplan, PhD. Chief Development Officer Recent failures in advanced Phase 3 clinical trials by Eli Lilly and Merck have been disappointing for the Alzheimer’s disease (AD) community. However, the…
Please view our latest corporate commentary from November 28th, 2016 “Results of Lilly’s Solanezumab trial confirm the “real” beta-Amyloid hypothesis” (PDF)
Critical Insight: Toxic soluble Amyloid beta oligomers (“prions”), not plaque, drive pathogenesis in Alzheimer’s disease Refinement of the Amyloid beta cascade hypothesis – Prions vs. Plaque The presence of Amyloid beta (Aβ) plaque is a hallmark of Alzheimer’s disease (AD)…
Executive Chairman’s Note: August 3, 2016 Highlights from the AAIC (Alzheimer’s Association International Conference) meeting held in Toronto July 23-28, 2016 The AAIC meeting was very positive for ProMIS Neurosciences. Most of our scientific and management team were able to…
The Root Cause of Alzheimer’s: Amyloid-beta and Tau prions ProMIS Science team’s review of the Alzheimer’s Scientific Literature Introduction to this White Paper ProMIS Neurosciences is focused on the discovery and development of precision treatments for neurodegenerative diseases. Novel therapeutic…